Sarepta CEO Kaye Announces Plans to Resign

Xconomy Boston — 

Sarepta Therapeutics (NASDAQ: SRPT) president and CEO Ed Kaye will resign on Sept. 20 “or some other future date” and will stay on as a board member and advisor afterwards, according to a regulatory filing. Kaye, Sarepta’s former chief medical officer, stepped in when ex-CEO Chris Garabedian resigned in 2015 and steered the company towards a major victory, the controversial FDA approval of Duchenne muscular dystrophy drug eteplirsen (Exondys 51) last September.